

05-05-2017

12:00 - 13:00 Industry Satellite Symposium 1 Room A

13:00 - 13:30 Welcome reception Main foyer

13:30 - 13:45 Opening and welcome Room B  
Chair: A. Nicholson, GB; M. Reck, DE

14:30 - 16:00 Management of brain metastases Room B

14:30 - 14:50 Molecular characteristics of brain metastases: Are they different?  
S. Ekman, SE

14:50 - 15:10 Systemic treatment of brain metastases  
J.C.-H. Yang, TW

15:10 - 15:30 Local management of brain metastases: The Surgeon's perspective  
M. De Praeter, BE

15:30 - 15:50 Radiation therapy of brain metastases  
J. Zindler, NL

15:50 - 16:00 Questions and Answers

14:30 - 16:00 The implications of TNM staging on clinical practice (in NSCLC) Room A

14:30 - 14:50 The impact on bronchoscopic staging  
F.J.F. Herth, DE

14:50 - 15:10 Surgical implications  
T. Mitsudomi, JP

15:10 - 15:30 M1b: Will it be useful to establish a new paradigm of oligometastatic disease?  
W. Eberhardt, DE

15:30 - 15:50 Combination of molecular markers and TNM staging to refine prognosis and therapy  
M. Tsao, CA

15:50 - 16:00 Questions and Answers

16:00 - 16:30 Coffee break Hall 1

16:30 - 18:00 Immunotherapy of non-small cell lung cancer Room B

16:30 - 16:50 First-line treatment

M. Reck, DE

16:50 - 17:10 Biomarkers

K. Kerr, GB

17:10 - 17:30 Combination approaches

N. Rizvi, US

17:30 - 17:50 Toxicities of immunecheckpoint blockers

J.-C. Soria, FR

17:50 - 18:00 Questions and Answers

16:30 - 18:00 Management of dyspnoea and cachexia in lung cancer Room A

16:30 - 16:50 Causes of dyspnoea in lung cancer and interventional management

D. Heigener, DE

16:50 - 17:10 Medical management of dyspnoea

S. Simon, DE

17:10 - 17:30 Pain management

M. Di Palma, FR

17:30 - 17:50 Cachexia

R. Gralla, US

17:50 - 18:00 Questions and Answers

18:30 - 20:00 Industry Satellite Symposium 2 Room A

06-05-2017

08:00 - 08:50 Lung cancer presenting through the emergency room Room A

08:00 - 08:15 Is emergency presentation of lung cancer a problem?  
T. Newsom-Davies, GB

08:15 - 08:30 Why does lung cancer present through the emergency room and how can outcomes be improved?  
H. Moller, GB

08:30 - 08:50 Discussion

08:00 - 08:50 How to classify progressive disease and clinical consequences: Definition and implication of progression Room W

08:00 - 08:15 The view of the Radiologist  
H. Prosch, AT

08:15 - 08:30 The view of the Oncologist  
R. Califano, GB

08:30 - 08:50 Discussion

08:00 - 08:50 Will immunotherapy be the standard of care in lung cancer? Room X

08:00 - 08:20 The role of immunotherapy in small cell lung cancer and other thoracic tumours  
J. Remon, ES

08:20 - 08:40 Does immunotherapy apply for all NSCLC patients?  
G. Mountzios, GR

08:40 - 08:50 Discussion

09:00 - 10:30 Immunotherapy for other thoracic tumours Room B

09:00 - 09:20 Perspectives in SCLC  
S. Peters, CH

09:20 - 09:40 Realities in mesothelioma  
S. Popat, GB

09:40 - 10:00 Thymic tumours  
G. Giaccone, US

10:00 - 10:20 T cell therapies  
A.-M. Dingemans, NL

10:20 - 10:30 Questions and Answers

09:15 - 10:15 Should we use newer generation targeted treatment upfront? Room A

09:15 - 09:25 Introduction and first vote

09:25 - 09:45 Yes  
D. Carbone, US

09:45 - 10:05 No  
J. Vansteenkiste, BE

10:05 - 10:15 Second vote and conclusions

10:30 - 11:00 Coffee break Hall 1

11:00 - 12:30 Management of non-oncogene driven NSCLC Room B

11:00 - 11:20 The revival of antiangiogenic therapies

R. Garcia Campelo, ES

11:20 - 11:40 Anti-EGFR therapies in unselected NSCLC patients

L. Paz-Ares, ES

11:40 - 12:00 Second line treatment and beyond: Selecting new agents in the arena for subsequent therapy

L. Horn, US

12:00 - 12:20 Elderly and frail patients: Choosing the optimal treatment option

M.J. Ahn, KR

12:20 - 12:30 Questions and Answers / Panel Discussion

11:00 - 12:30 The role of the pathologist in guiding therapy Room A

11:00 - 11:20 Conventional therapy for lung cancer

M. Tsao, CA

11:20 - 11:40 Targeted therapy for lung cancer

S. Lantuejoul, FR

11:40 - 12:00 Immunomodulatory therapy for lung cancer

F.R. Hirsch, US

12:00 - 12:20 Therapy for mesothelioma and other thoracic malignancies

A. Nicholson, GB

12:20 - 12:30 Questions and Answers / Panel Discussion

11:00 - 12:30 Prevention and smoking cessation Room C

11:00 - 11:20 Can food prevent lung cancer?

11:20 - 11:40 The environmental factors we should address to reduce the incidence of lung cancer in non-smokers  
P. Boffetta, US

11:40 - 12:00 The e-cigarette: New data with longer follow-up  
A. Stoebner-Delbarre, FR

12:00 - 12:20 Does smoking cessation improve survival in metastatic lung cancer?  
V. Westeel, FR

12:20 - 12:30 Questions and Answers / Panel Discussion

11:00 - 12:30 Standards for high-dose radiotherapy in lung cancer Room W

11:00 - 11:20 ESTRO practice guidelines for lung SABR delivery  
M. Guckenberger, CH

11:20 - 11:40 Evidence-based guidelines for delivery of curative radiotherapy in stage III NSCLC  
R. Dziadziuszko, PL

11:40 - 12:00 ESTRO practice guidelines for combining radiotherapy with targeted agents  
D. De Ruyscher, NL

12:00 - 12:20 Extra-cranial oligometastatic NSCLC: Techniques, doses and timing  
G. Hanna, GB

12:20 - 12:30 Questions and Answers / Panel Discussion

11:00 - 12:30	Rare thoracic malignancies	Room X
11:00 - 11:20	Isolated lung perfusion for pulmonary metastases from sarcoma <u>P. Van Schil</u> , BE	
11:20 - 11:40	Local control in primary sarcoma of the chest wall <u>K. Wiebe</u> , DE	
11:40 - 12:00	Robotic extended thymectomy for early stage thymoma <u>F. Melfi</u> , IT	
12:00 - 12:20	Diagnostic workup and treatment of bronchopulmonary carcinoid tumours <u>S. Schmid</u> , DE	
12:20 - 12:30	Questions and Answers / Panel Discussion	
12:30 - 13:00	Poster Display session	Hall 1
13:00 - 14:00	Industry Satellite Symposium 3	Room A
14:10 - 14:40	Keynote lecture: Genetic profiling of lung cancer	Room B
14:10 - 14:40	Genetic profiling of lung cancer <u>M. Meyerson</u> , US	
14:45 - 16:15	Proffered Papers 1	Room B

14:45 - 16:15	Liquid biopsies in NSCLC	Room A
14:45 - 15:00	Blood-based techniques for detecting tumour-derived biomarkers in lung cancer <u>N. Normanno</u> , IT	
15:00 - 15:15	Detection of CTCs in peripheral blood of lung cancer <u>H. Wikman</u> , DE	
15:15 - 15:30	Circulating blood platelets: A novel liquid biopsy biosource <u>T. Würdinger</u> , NL	
15:30 - 15:45	Role of cfDNA to monitor EGFR dynamic changes and resistance in blood <u>T.S.K. Mok</u> , CN	
15:45 - 16:15	Panel discussion	
14:45 - 15:45	Poster Discussion 1	Room W
16:15 - 16:45	Coffee break	Hall 1
16:45 - 18:15	New molecular targets of interest beyond ALK and EGFR	Room B
16:45 - 17:05	Targeting RAS <u>E. Smit</u> , NL	
17:05 - 17:25	Targeting B-RAF <u>D. Planchard</u> , FR	
17:25 - 17:45	Targeting NTRK <u>F. de Braud</u> , IT	
17:45 - 18:05	Targeting MET <u>M. Awad</u> , US	
18:05 - 18:15	Questions and Answers	
16:45 - 18:15	Proffered papers 2	Room A
18:40 - 19:40	Industry Satellite Symposium 4	Room A
18:40 - 19:40	Industry Satellite Symposium 5	Room C



## 07-05-2017

08:00 - 08:50 Optimal management of stage III NSCLC in 2017 Room A

08:00 - 08:15 Surgical approach  
A.D.L. Sihoe, CN

08:15 - 08:30 Radiotherapy approach  
S. Senan, NL

08:30 - 08:50 Discussion

08:00 - 08:50 Multiple lung nodules Room W

08:00 - 08:15 Staging: Diagnostic algorithms  
F. Detterbeck, US

08:15 - 08:30 Therapeutic algorithms  
K. Suzuki, JP

08:30 - 08:50 Discussion

09:00 - 10:30 Management of NSCLC with resistance to first line targeted therapy Room B

09:00 - 09:20 Management of T790M positive disease after EGFR TKI failure  
C. Lovly, US

09:20 - 09:40 Management of T790M negative disease after EGFR TKI failure  
M. Krebs, GB

09:40 - 10:00 Management of drug resistance in ALK positive NSCLC  
D. Tan, SG

10:00 - 10:20 Management of resistance in other targets beyond ALK and EGFR  
L. Friboulet, FR

10:20 - 10:30 Questions and Answers

09:00 - 10:30 Proffered Papers 3 Room C

09:15 - 10:15 Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC? Room A

09:15 - 09:25 Introduction and first vote

09:25 - 09:45 Yes  
R. Herbst, US

09:45 - 10:05 No  
B. Besse, FR

10:05 - 10:15 Second vote and conclusions

10:30 - 11:00 Coffee break Hall 1

11:00 - 12:30 Molecular understanding of lung cancer: The role of the host and environment Room B

11:00 - 11:20 Role of the microbiome in lung cancer  
B. Cookson, GB

11:20 - 11:40 Tumour clonal symbiosis  
M. Janiszewska, US

11:40 - 12:00 Homotypic and heterotypic interactions in lung carcinogenesis  
L.M. Montuenga, ES

12:00 - 12:20 Tumour mutations that alter antigen presentation/signalling  
M. Meyerson, US

12:20 - 12:30 Questions and Answers

11:00 - 12:30 What should non-Surgeons expect from Surgeons? Room A

11:00 - 11:20 Minimal requirements for surgical participation in CT screening programmes  
J.H. Pedersen, DK

11:20 - 11:40 Surgeon-led randomised trials: The case of mesothelioma  
J. Edwards, GB

11:40 - 12:00 The approach of Surgeons towards N2 NSCLC  
G. Massard, FR

12:00 - 12:20 The impact of international surgical registries on multidisciplinary decisions: The case of thymic tumours and NET  
P.L. Filosso, IT

12:20 - 12:30 Questions and Answers

11:00 - 12:30 SCLC: New insights Room C

11:00 - 11:20 What is the optimal thoracic radiotherapy in limited stage SCLC?  
C. Faivre-Finn, GB

11:20 - 11:40 Can brain control be improved beyond PCI?  
A. Grosu, DE

11:40 - 12:00 New therapies, new era?  
N. Reguart, ES

12:00 - 12:20 What can CDX models teach us?  
C. Dive, GB

12:20 - 12:30 Questions and Answers

12:30 - 13:00 Poster Display session Hall 1

13:00 - 14:00 Industry Satellite Symposium 6 Room A

13:00 - 14:00 Industry Satellite Symposium 7 Room C

14:10 - 14:40	Keynote lecture: Molecular clonal development of lung cancer	Room B
14:10 - 14:40	Molecular clonal development of lung cancer <u>C. Swanton</u> , GB	
14:45 - 16:15	Patient with early stage disease and compromised lung function	Room A
14:45 - 15:15	Patient assessment and shared decision-making <u>D.R. Baldwin</u> , GB	
15:15 - 15:45	The case for limited surgery <u>A.D.L. Sihoe</u> , CN	
15:45 - 16:15	The argument for SBRT <u>K. Franks</u> , GB	
14:45 - 16:15	Malignant pleural mesothelioma	Room C
14:45 - 15:05	Genetics of mesothelioma <u>M. Carbone</u> , US	
15:05 - 15:25	Prognostic indices <u>I. Opitz</u> , CH	
15:25 - 15:45	Surgical approach: P/D versus EPP <u>D. Waller</u> , GB	
15:45 - 16:05	Combined modality therapy <u>J. van Meerbeeck</u> , BE	
16:05 - 16:15	Questions and Answers	
14:45 - 15:45	Poster Discussion 3	Room W
16:15 - 16:45	Coffee break	Hall 1
16:45 - 18:15	ESMO-IASLC Best Abstracts	Room B

16:45 - 18:15 4th ESO Lung Cancer Observatory: Innovation and care in the next 12 months Room W

16:45 - 16:55 Prevention: Are we progressing in anti-tobacco campaigns in the world?

16:55 - 17:05 Screening: Where will it be in 2018?

17:05 - 17:15 Surgery or radiation: When is it a choice?

17:15 - 17:25 Radiation oncology: Will guidelines change?

17:25 - 17:35 What to ask your pathologist today and in 2018?

17:35 - 17:45 Developments in medical oncology: What practice changing studies will mature in 2018?

17:45 - 17:55 The patient's perspective

17:55 - 18:15 Panel discussion

18:40 - 19:40 Industry Satellite Symposium 8 Room A

18:40 - 19:40 Industry Satellite Symposium 9 Room C

08-05-2017

11:20 - 12:50	ESMO recommendations	Room A
11:20 - 11:40	NSCLC <u>S. Novello</u> , IT	
11:40 - 12:00	SCLC <u>M. Frueh</u> , CH	
12:00 - 12:20	Mesothelioma <u>P. Baas</u> , NL	
12:20 - 12:40	Thymic <u>N. Girard</u> , FR	
12:40 - 12:50	Questions and Answers	
12:50 - 13:00	Closing remarks Chair: A. Nicholson, GB; M. Reck, DE	Room A